Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases

  • Financing co-led by Sunstone Life Science Ventures and Sound Bioventures with participation from Industrifonden, Innovestor’s Life Science Fund and P53 Invest
  • Discovery of a novel mechanism with the potential to prevent the death of neurons in neurodegenerative diseases
  • First-in-Class, lead drug candidate advances into clinical development in a Phase 1b study
  Aarhus, Denmark March 14th, 2023: Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The…
Read more